Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2026 · 10-Q
Revenue$9.13M$9.13M−1.1% vs Q2 2025 Net Income$158.00K$158.00KN/M vs Q2 2025 EPS Diluted$0.01$0.01N/M vs Q2 2025 Gross Profit$5,653,000+7.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived$98,000−81.2% Free Cash Flowderived$41,000— Margins · derivedGross margin61.9%+4.8 pt vs Q2 2025
Operating margin3.5%+8.6 pt vs Q2 2025
Net margin1.7%+8.7 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 10, 2026 · 41 d after period end